Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/19/2025 | $76.00 | Overweight | Piper Sandler |
| 1/10/2025 | $72.00 | Overweight | Piper Sandler |
| 10/11/2024 | $50.00 | Buy | Rodman & Renshaw |
| 11/1/2021 | $9.00 | Buy | HC Wainwright & Co. |
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
SC 13D/A - Monopar Therapeutics (0001645469) (Subject)
SC 13G - Monopar Therapeutics (0001645469) (Subject)
SC 13G - Monopar Therapeutics (0001645469) (Subject)
SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
10-Q - Monopar Therapeutics (0001645469) (Filer)
8-K - Monopar Therapeutics (0001645469) (Filer)
Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan
Piper Sandler resumed coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $76.00
Piper Sandler initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $72.00
Rodman & Renshaw initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $50.00
Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t
WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini
WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, a leading global conference in liver disease. The data support ALXN1840 as a potential treatment for Wilson disease
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar's late-breaker poster presentation is available at the following link: https://www.monopartx.com/pipeline/ALXN1840/EASL-poster-may-2025. The poster supports the potential use o
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025. Late-breaker provides an opportunity to present "
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)